Empaflo M 12.5/1000 mg Tablets are a fixed-dose combination of Empagliflozin (12.5 mg), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin (1000 mg), a biguanide. This dual therapy is indicated for the management of type 2 diabetes mellitus in adults, providing complementary mechanisms of action to improve glycemic control: Empagliflozin lowers blood glucose by reducing renal glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake. Together, they help achieve better blood sugar control, reduce cardiovascular risk, and support long-term diabetes management.
